Literature DB >> 17073579

Metabolism of green tea catechins: an overview.

Wan Yong Feng1.   

Abstract

Green tea is one of the most popular beverages worldwide. Its major components include (-)-epicatechin ((-)-EC), (-)-epicatechin-3-gallate (ECG) (-)-epigallocatechin (EGC) and (-)-epigallocatechin-3-gallate (EGCG). It has demonstrated strong antioxidative, anti-inflammatory and anti-cancerous properties and attracted a great deal of interest over last several years. However, there is some discrepancy between the results from human pidemiological studies and cultured cell and animal models. Two reasons for its limited in vivo activities have been considered: metabolism and bioavailability. Recent studies have demonstrated that green tea catechins undergo methylation, glucuronidation and sulfation in in vitro systems and in animals and in humans. It has been also found that efflux transporters Pgp, MRP1 and MRP2 play roles in the absorption and excretion of green tea catechins. Several processes including intestinal metabolism, microbial metabolism, hepatic metabolism and chemical degradation have been found to be involved in the fate of green tea, and to be responsible for its low availability in animals, and most likely also in humans. Pharmacokinetics, absorption, distribution, drug metabolism and excretion properties of green tea provide a better understanding for its in vivo activities. In this article, drug metabolism and microbial metabolism of green tea catechins in in vitro systems and in animals and in humans will be reviewed. It also covers the factors affecting their biotransformation and bioavailability: drug-drug inhibitory and inductive interactions of phase I and phase II enzymes, inhibition of non-drug-metabolizing enzymes, transporters, chemical instability, epimerization and interindividual variability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073579     DOI: 10.2174/138920006778520552

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  60 in total

1.  Enzymatic synthesis of substituted epicatechins for bioactivity studies in neurological disorders.

Authors:  Jack W Blount; Mario Ferruzzi; Dan Raftery; Giulio M Pasinetti; Richard A Dixon
Journal:  Biochem Biophys Res Commun       Date:  2011-12-07       Impact factor: 3.575

2.  Glucuronidation and methylation of procyanidin dimers b2 and 3,3″-di-o-galloyl-b2 and corresponding monomers epicatechin and 3-o-galloyl-epicatechin in mouse liver.

Authors:  Suraj P Shrestha; John A Thompson; Michael F Wempe; Mallikarjuna Gu; Rajesh Agarwal; Chapla Agarwal
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

3.  Therapy effects of green tea in a patient with systemic light-chain amyloidosis.

Authors:  Derliz Mereles; Erich E Wanker; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2008-03-03       Impact factor: 5.460

Review 4.  Botanicals for age-related diseases: from field to practice.

Authors:  Connie M Weaver; Stephen Barnes; J Michael Wyss; Helen Kim; Dorothy M Morré; D James Morré; James E Simon; Mary Ann Lila; Elsa M Janle; Mario G Ferruzzi
Journal:  Am J Clin Nutr       Date:  2008-02       Impact factor: 7.045

5.  Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site.

Authors:  Changhong Li; Ming Li; Pan Chen; Srinivas Narayan; Franz M Matschinsky; Michael J Bennett; Charles A Stanley; Thomas J Smith
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

Review 6.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

7.  Structural identification of novel glucoside and glucuronide metabolites of (-)-epigallocatechin-3-gallate in mouse urine using liquid chromatography/electrospray ionization tandem mass spectrometry.

Authors:  Shengmin Sang; Chung S Yang
Journal:  Rapid Commun Mass Spectrom       Date:  2008-11       Impact factor: 2.419

8.  Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.

Authors:  Adam Smith; Brian Giunta; Paula C Bickford; Michael Fountain; Jun Tan; R Douglas Shytle
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

9.  Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs.

Authors:  Huanjie Yang; Dong Kui Sun; Di Chen; Qiuzhi Cindy Cui; Yan Yan Gu; Tao Jiang; Wei Chen; Sheng Biao Wan; Q Ping Dou
Journal:  Cancer Lett       Date:  2009-12-03       Impact factor: 8.679

Review 10.  Tea and health: studies in humans.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.